Problematic cannabis use amongst those with severe mental health problems in an inner city area of the UK

Addictive Behaviors

Volumn 27, Issue 2, 2002, Pages 261-273

  Graham, Hermine L ^a,b   Maslin, Jenny ^a,b  

^a BIRMINGHAM AND SOLIHULL MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Cannabis and psychosis; Cannabis use; Dual diagnosis; Prevalence survey; Severe mental health problems

Indexed keywords

ALCOHOL; CANNABIS;

ADULT; AGED; ARTICLE; CITY; COMMUNITY CARE; COPING BEHAVIOR; DELUSION; DRUG USE; FEMALE; HEALTH PRACTITIONER; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MENTAL HEALTH SERVICE; PERSONALITY DISORDER; PREVALENCE; QUESTIONNAIRE; SCHIZOPHRENIA; SUBSTANCE ABUSE; UNITED KINGDOM; URBAN AREA;

ADOLESCENT; ADULT; AGED; COMMUNITY MENTAL HEALTH SERVICES; FEMALE; GREAT BRITAIN; HUMANS; MALE; MARIJUANA ABUSE; MENTAL DISORDERS; MIDDLE AGED; URBAN POPULATION;

EID: 0036135401     PISSN: 03064603     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4603(01)00173-3     Document Type: Article

References (45)

1. Effect of substance misuse on early psychosis
2. Missed diagnosis of substance abuse in psychiatric patients
3. Substance abuse in schizophrenia: service utilization and costs
4. Substance abuse among patients with treatment resistant schizophrenia: characteristics and implications for clozapine therapy
5. Severe mental illness and addictions: assessment considerations
6. Prevalence of substance abuse by seriously mentally ill patients in a partial hospital program
7. Development and validation of a three-dimensional measure of drinking motives
8. Schizophrenia and substance abuse: prevalence issues
9. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users
10. The role of dysfunctional beliefs in individuals who experience psychosis and use substances: implications for cognitive therapy and medication adherence
11. Effects of cannabis abuse on people with serious mental health problems
12. Prevalence of substance abuse in a psychiatric evaluation unit
13. Substance use and schizophrenia
14. Harmful use of psychotropic substances by schizophrenics: coincidence, patterns of use and motivation
15. Prevalence and patterns of dual diagnosis among psychiatric inpatients
16. Treating substance use disorders with cognitive therapy: lessons learned and implications for the future
17. Cannabis abuse and the course of recent onset schizophrenic disorders
18. Cannabis use in a large sample of psychiatric admissions
19. An improved evaluation instrument for substance abuse patients: the Addiction Severity Index
20. Drug and alcohol problems among individuals with severe mental illness in South London
21. Dual diagnosis: a review of etiological theories
22. Expectations and motives for substance use in schizophrenia
23. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates
24. Reversing a history of unmet needs: approaches to care for persons with co-occurring addictive and mental disorders
25. Co-morbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study
26. Cannabis use in the community
27. Co-morbid substance abuse and recovery from acute psychiatric relapse
28. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption - II
29. Dual diagnosis patients: substance abuse by the severely mentally ill
30. Cannabis and cannabis withdrawal
31. Substance abuse and bipolar affective disorder
32. Prevalence of alcohol and drug abuse in schizophrenic inpatients
33. Substance abuse and psychosis: chicken or the egg?
34. Substance use among the mentally ill: prevalence, reasons for use and effects on illness
35. Methodological considerations in the diagnosis of coexisting psychiatric disorders in substance abusers
36. Abuse of and dependence on stimulants and anorexigenic drugs in psychiatric inpatients